Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam J N Raymakers

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
JAMA Dermatology|January 31, 2024
Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis BullosaAdam J N Raymakers, Aaron S Kesselheim, Arash Mostaghimi, et al.
Journal of Cannabis Research|January 26, 2026
Using a discrete choice experiment to estimate individual preferences to medicate cancer-related symptoms with cannabisHelen McTaggart-Cowan, Adam J N Raymakers, Sara Izadi-Najafabadi, et al.
The Journal of Pediatrics|May 19, 2025
Pediatric Exclusivity-Associated Revenues and Labeling Changes, 2013-2023Ian T T Liu, Adam J N Raymakers, Ameet Sarpatwari, et al.
Journal of Cancer Policy|February 2, 2025
An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncologyAdam J N Raymakers, Leah Z Rand, William B Feldman, et al.
Journal of Cancer Policy|May 13, 2022
Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trialsAdam J N Raymakers, Dean A Regier, Stuart J Peacock, et al.
Scientific Reports|July 27, 2024
Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysisSamantha Pollard, Brandon Chan, Alina S Gerrie, et al.
Healthcare Management Forum|October 25, 2019
Evidence, values, and funding decisions in Canadian cancer systemsStuart J Peacock, Dean A Regier, Adam J N Raymakers, et al.
The Journal of Rheumatology|August 3, 2016
Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?Adam J N Raymakers, Nicole W Tsao, Carlo A Marra, et al.
Health Affairs (Project Hope)|March 3, 2025
Changes In Biologic Drug Revenues After Administrative Patent ChallengesAdam J N Raymakers, Victor L Van de Wiele, Aaron S Kesselheim, et al.
BMJ Open|April 26, 2022
Health-related quality of life measures in incarcerated populations: protocol for a scoping reviewHabeba Talaat, Seniyyeh Bashayan, Adam J N Raymakers, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
JAMA Dermatology|January 31, 2024
Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis BullosaAdam J N Raymakers, Aaron S Kesselheim, Arash Mostaghimi, et al.
Journal of Cannabis Research|January 26, 2026
Using a discrete choice experiment to estimate individual preferences to medicate cancer-related symptoms with cannabisHelen McTaggart-Cowan, Adam J N Raymakers, Sara Izadi-Najafabadi, et al.
The Journal of Pediatrics|May 19, 2025
Pediatric Exclusivity-Associated Revenues and Labeling Changes, 2013-2023Ian T T Liu, Adam J N Raymakers, Ameet Sarpatwari, et al.
Journal of Cancer Policy|February 2, 2025
An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncologyAdam J N Raymakers, Leah Z Rand, William B Feldman, et al.
Journal of Cancer Policy|May 13, 2022
Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trialsAdam J N Raymakers, Dean A Regier, Stuart J Peacock, et al.
Scientific Reports|July 27, 2024
Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysisSamantha Pollard, Brandon Chan, Alina S Gerrie, et al.
Healthcare Management Forum|October 25, 2019
Evidence, values, and funding decisions in Canadian cancer systemsStuart J Peacock, Dean A Regier, Adam J N Raymakers, et al.
The Journal of Rheumatology|August 3, 2016
Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?Adam J N Raymakers, Nicole W Tsao, Carlo A Marra, et al.
Health Affairs (Project Hope)|March 3, 2025
Changes In Biologic Drug Revenues After Administrative Patent ChallengesAdam J N Raymakers, Victor L Van de Wiele, Aaron S Kesselheim, et al.
BMJ Open|April 26, 2022
Health-related quality of life measures in incarcerated populations: protocol for a scoping reviewHabeba Talaat, Seniyyeh Bashayan, Adam J N Raymakers, et al.
Pageof 4